Skip to main content
    Fact-checked by the Peptide Authority Editorial Board · Last reviewed:
    Claim review

    GHK-Cu + BPC-157 — claim review

    Marketed as a 'comprehensive skin + tissue regeneration' combination. GHK-Cu has legitimate topical cosmetic evidence; BPC-157 has none in humans. The combination has zero human trial support and the leap from topical cosmetic-grade GHK-Cu to injectable stack use is not evidence-based.

    What people claim about this combination

    • “Triple-pathway skin and tissue regeneration”
    • “Reverses biological skin ageing while repairing injury underneath”
    • “Cosmetic-clinic-grade results from research peptides”
    • “Safer than retinoids because it's peptide-based”

    What the evidence actually says

    GHK-Cu has reasonable peer-reviewed evidence as a topical cosmetic ingredient — collagen-synthesis support, fibroblast activity, improvements in fine-line appearance in well-controlled cosmetic trials. This evidence is for finished topical products at formulated concentrations, not for injectable peptide vials sold via research-chemical retailers.

    BPC-157 has substantial preclinical (rodent) tissue-healing data but zero published human randomised trials for any indication. Promotional combination claims are mechanistic story-telling, not evidence.

    UK regulatory and safety framing

    Topical cosmetic GHK-Cu is regulated as a cosmetic ingredient. Injectable GHK-Cu and BPC-157 are unlicensed under UK medicines law. Clinics offering them as medical treatments engage UK advertising-of-medicines rules. See peptide clinics and UK law.

    Safer alternatives

    • Topical GHK-Cu in finished, regulated cosmetic skincare products.
    • Daily sunscreen, topical tretinoin — the best-evidenced anti-ageing topicals.
    • NHS dermatology referral for genuine skin or wound concerns.
    • NHS physiotherapy + sports-medicine pathways for tissue injury.

    Frequently asked questions

    Is GHK-Cu + BPC-157 a proven wound-healing protocol?
    No. GHK-Cu has reasonable topical cosmetic-skincare evidence at clinical concentrations. BPC-157 has preclinical-only evidence with no human RCT for any indication. The combination has zero human trial data.
    Is the topical GHK-Cu in this stack the same as injection-grade?
    No. The well-studied GHK-Cu evidence is for finished topical cosmetic products. Injectable GHK-Cu sold by online research-peptide retailers is a different supply chain with no human-use data for injection.
    Is BPC-157 legal in the UK?
    BPC-157 is not a licensed UK medicine. Selling it with human-use claims engages UK medicines regulation. See /legal/bpc-157-legal-uk.
    Are athletes at risk from this combination?
    BPC-157 is treated by WADA as prohibited under S0. GHK-Cu status is less clear-cut but anti-doping uncertainty alone is a strict-liability risk. See /safety-centre/athlete-anti-doping-risks.
    Why is this combination so popular online?
    GHK-Cu has genuine cosmetic-skincare evidence that lends marketing credibility, and BPC-157 has a memorable 'body protection compound' mechanistic story. Combined, they sell a 'skin + structure' regeneration narrative the evidence does not support for injectable use.

    Last reviewed:

    Next review due:

    Spotted an error or something out of date? Send a correction.

    Related